These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Zhang JY Cancer Detect Prev; 2004; 28(2):114-8. PubMed ID: 15068835 [TBL] [Abstract][Full Text] [Related]
23. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Egloff AM; Vella LA; Finn OJ Cancer Res; 2006 Jan; 66(1):6-9. PubMed ID: 16397206 [TBL] [Abstract][Full Text] [Related]
24. [Telomerase, a universal target in immunotherapy strategies against tumor?]. Rousseau R; Soria JC Bull Cancer; 2000 Dec; 87(12):895-901. PubMed ID: 11174119 [TBL] [Abstract][Full Text] [Related]
25. [Immediate type reaction to intradermally administered tumor polysaccharides]. Okazaki T; Namae A; Kto K; Ikeda M; Higuchi Y Igaku To Seibutsugaku; 1971 Dec; 83(6):359-63. PubMed ID: 5172625 [No Abstract] [Full Text] [Related]
26. [Present status of tumor antigen testing]. Kawai T Rinsho Byori; 1983 Dec; 31(12):1294-9. PubMed ID: 6676483 [No Abstract] [Full Text] [Related]
27. [Present and future of tumor markers]. Kawai T Rinsho Byori; 1987 Feb; 35(2):167-71. PubMed ID: 3586352 [No Abstract] [Full Text] [Related]
28. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"]. Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906 [TBL] [Abstract][Full Text] [Related]
29. [The function of tumor specific antigen (MAGE) in tumor immunotherapy]. Fang JB; Wang L Sheng Li Ke Xue Jin Zhan; 2005 Jul; 36(3):273-5. PubMed ID: 16270835 [No Abstract] [Full Text] [Related]
30. Tumor-associated antigens and biomarkers in cancer and immune therapy. Malyankar UM Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745 [TBL] [Abstract][Full Text] [Related]
31. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives]. Gaugler B; Olive D Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993 [TBL] [Abstract][Full Text] [Related]
32. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Coggin JH; Barsoum AL; Rohrer JW; Thurnher M; Zeis M Anticancer Res; 2005; 25(3c):2345-55. PubMed ID: 16080461 [TBL] [Abstract][Full Text] [Related]
33. Immunization in tumor prevention. Forni G; Curcio C; Spadaro M; Iliffe J; Quaglino E; Di Carlo E; Musiani P; Lollini PL Int Immunopharmacol; 2003 Aug; 3(8):1151-8. PubMed ID: 12860170 [TBL] [Abstract][Full Text] [Related]
35. How to analyze ex vivo T-cell responses in cancer patients. Nagorsen D; Marincola FM In Vivo; 2002; 16(6):519-25. PubMed ID: 12494896 [TBL] [Abstract][Full Text] [Related]
36. [Quantitative characteristics of the cellular link of immunity and a lymphocytic response to tumor-associated antigens in patients with tuberculosis and malignant neoplasms of the lung]. Autenshlius AI; Ivanova GG; Ogirenko AP; Ageeva TA; Vasil'ev NE Probl Tuberk; 2002; (4):48-50. PubMed ID: 12125255 [TBL] [Abstract][Full Text] [Related]
37. Targets of protective tumor immunity. Dranoff G Ann N Y Acad Sci; 2009 Sep; 1174():74-80. PubMed ID: 19769739 [TBL] [Abstract][Full Text] [Related]
38. [Development of personalized peptide vaccines for advanced cancer patients]. Yamada A Rinsho Ketsueki; 2005 Jun; 46(6):433-8. PubMed ID: 16447725 [No Abstract] [Full Text] [Related]
39. The carapace of the cancer cell. The Osler oration 1984. Harris H J R Coll Physicians Lond; 1984 Jul; 18(3):161-5. PubMed ID: 6381720 [No Abstract] [Full Text] [Related]